While Bollywood was busy remaking old hits, Innova Captab decided to remix its own business. From splitting into “CDMO + Branded Generics” to showing off its shiny new ₹480 cr Jammu plant, management basically said: “New set, same actors, better script.” But then API prices fell like Sensex on Budget Day, and suddenly revenue targets looked like wishlists. Still, with exports booming and branded generics partying at +59% growth, Innova wants you to believe it’s on the cusp of becoming the next CDMO blockbuster. Stick around—because this drama has both masala and margin math.
2. At a Glance
Revenue ₹352 cr (+19% YoY) – Growth despite API price crash; props for that.
EBITDA margin 16.1% (+100 bps) – A rare pharma company on a diet that worked.
PAT ₹31 cr (+5% YoY) – Growth slowed by depreciation & finance costs.
CDMO revenue ₹249 cr (+8%) – Still the core, even if APIs misbehaved.
Branded Generics ₹101 cr (+59%) – The real hero; India + exports fired up.
Jammu plant revenue ₹60 cr (Q1) – Baby steps, but already near EBITDA breakeven.
3. Management’s Key Commentary
Vinay Lohariwala (MD): “We reorganized into CDMO and Branded Generics for clarity.” (Translation: Fancy PowerPoint structure = investors happy, reality unchanged.)
On Jammu plant: “Built with ₹480 cr capex, full automation, CGMP norms.” (Translation: We basically made the pharma version of an iPhone factory, now waiting for orders.)
On CDMO: “Partner of choice for 300 companies, 3,700 products.” (Translation: Too many SKUs, hope someone’s tracking them all.)
On API price crash: “Potassium clavulanate dropped 30%, created turmoil.” (Translation: Our margins are on a rollercoaster, and APIs drive the cart.)
On exports: “Growth driven by ROW geographies, cephalosporin capacity shift.” (Translation: Domestic moved to Jammu, Baddi freed up for export jugglery.)
On Jammu outlook: “At ₹100 cr quarterly revenue, PAT positive.” (Translation: Until then, pray GST incentives keep us afloat.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹352 cr
+19%
APIs crashed, but sales still stitched together.
EBITDA – The Sidekick
₹57 cr
+28%
Incentives + Jammu ramp-up boosted.
EBITDA Margin – Diva
16.1%
+100 bps
Margins look glam, thanks to pass-through model.
PAT – The Survivor
₹31 cr
+5%
Depreciation + finance dragged party down.
CDMO – The Old Guard
₹249 cr
+8%
Still 71% of business, steady but slower.
Branded Generics – Star
₹101 cr
+59%
Explosive growth, domestic + export combined.
Jammu Plant
₹60 cr
N/A
EBITDA breakeven already, PAT breakeven at ₹100 cr.
